Form 4: Suvretta Capital Boosts Benitec Biopharma Stake

Suvretta Capital Management and its affiliated funds increased their beneficial ownership in Benitec Biopharma Inc. through multiple open market purchases in December 2025.

Summary

• Suvretta Capital Management, LLC, along with Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., and Aaron Cowen, collectively increased their beneficial ownership in Benitec Biopharma Inc. (BNTC).
• The reporting persons acquired a total of 46,141 shares of Benitec Biopharma Inc. common stock through open market purchases between December 18, 2025, and December 22, 2025.
• Purchases were made at weighted average prices ranging from $11.24 to $12.08 per share.
• Following these transactions, the Averill Master Fund, Ltd. beneficially owns 9,577,475 shares, and Averill Madison Master Fund, Ltd. beneficially owns 1,826,653 shares.
• The total beneficial ownership by the Funds (Averill Master Fund and Averill Madison Master Fund) after these transactions is 11,404,128 shares.
• Suvretta Capital Management, LLC is the investment manager for the Funds, and Aaron Cowen may be deemed to control Suvretta Capital, thus indirectly beneficially owning the shares held by the Funds.
• The Funds are deemed directors by deputization due to Kishan Mehta, a portfolio manager of Suvretta Capital, serving on the board of directors of Benitec Biopharma Inc.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant open market purchases by a 10% owner and entities with director representation. This indicates strong conviction from a major institutional investor in the company's value and future performance.

Positives

• Significant open market purchases by a 10% owner and entities with director representation indicate strong confidence in Benitec Biopharma Inc.'s future prospects.
• Increased institutional ownership by Suvretta Capital Management and its affiliated funds can be viewed as a positive signal for other investors.

Future Outlook

No specific forward-looking statements or guidance are provided in this transactional filing.

Management Comments

• Aaron Cowen disclaims beneficial ownership of the shares reported except to the extent of any indirect pecuniary interest therein.
• The Reporting Persons undertake to provide full information regarding the number of shares purchased at each separate price within the reported ranges upon request to the Issuer, any security holder, or the SEC staff.

Industry Context

This transaction reflects continued institutional interest in the biopharmaceutical sector, with a significant investor increasing its stake in a company, potentially signaling confidence in its long-term prospects within the industry.

Corporate Governance

Related Party Transactions

• The reported purchases of common stock were made by Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd., which are managed by Suvretta Capital Management, LLC. Suvretta Capital Management, LLC is a 10% owner and has a representative on the issuer's board of directors, making these transactions related-party dealings under SEC rules.

Stakeholder Impact

• Shareholders may view the increased stake by a major institutional investor and director-affiliated entities as a vote of confidence, potentially leading to increased investor interest and positive share price movement.
• The company's management and board may feel validated by the continued investment from a significant stakeholder.

Key Dates

Recommendation

The significant open market purchases by Suvretta Capital Management and its affiliated funds, which are 10% owners and have director representation, signal strong insider confidence in Benitec Biopharma Inc. Such substantial buying by a sophisticated institutional investor often precedes positive developments or reflects an undervalued assessment, making it a compelling 'buy' signal for seasoned investors.

Keywords

Benitec Biopharma, BNTC, Suvretta Capital Management, Insider Buying, Institutional Investment, Stock Purchase, Beneficial Ownership, Biopharma